{"filings":[{"id":954211,"accession_number":"0001193125-26-264392","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2026-06-09T22:11:53+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Brian Thomas resigns from Metagenomi board; shareholders re-elect Eckhardt, Bjerkholt and ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026, with no disagreement with the company.","Juergen Eckhardt and Eric Bjerkholt elected as Class II directors to serve until 2029 annual meeting.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 18,483,295 votes for, 51,847 against.","Quorum of 19,116,207 shares present out of 37,647,057 outstanding at the June 9, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13048,"accession_number":"0001193125-26-216763","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2026-05-11T20:09:09+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.","MGX-001 for hemophilia A: regulatory submission including IND planned for Q4 2026, first-in-human trials in 2027.","Kapil Saxena, MD, appointed to lead clinical development for MGX-001; prior roles at Autolus, Bayer, Daiichi Sankyo.","R&D expenses $19.3M in Q1 2026 (vs $25.1M Q1 2025); G&A $6.5M (vs $6.8M).","Nature publication on compact CRISPR nuclease MG119-28 with enhanced editing efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1248000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108501,"accession_number":"0001193125-26-093943","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.","R&D expenses $94.4M in FY2025 (down 13.6% from FY2024); G&A $26.8M (down 16.3% from $32.0M).","MGX-001 hemophilia A pre-IND meeting completed; IND filing expected 4Q 2026, clinical trials in 2027.","Preclinical NHP data showed curative FVIII levels; in vivo proof-of-concept for Antithrombin deficiency also achieved.","Corporate name changed to Metagenomi Therapeutics; Ionis collaboration advancing APOC3 target in cardiometabolic indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108502,"accession_number":"0001193125-26-009928","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Metagenomi renames to Metagenomi Therapeutics; hemophilia A program on track for IND in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to Metagenomi Therapeutics, Inc. effective Jan 12, 2026; ticker MGX unchanged.","Lead program MGX-001: pre-IND meeting completed; IND/CTA on track for Q4 2026.","Preclinical data showed curative FVIII activity in NHPs with no off-target editing.","Cash runway extended to Q4 2027 following strategic pipeline prioritization.","Jian Irish appointed CEO as part of strategic evolution toward in vivo gene editing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124937,"accession_number":"0001193125-25-276135","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.","Workforce reduced by 25%; early discovery and platform research deprioritized.","Jian Irish promoted to CEO; founder Brian Thomas remains on Board; Willard Dere named Board Chair.","MGX-001 hemophilia A preclinical data: curative FVIII activity in NHPs at proposed clinical dose averaging 49%.","Pre-IND meeting expected Q4 2025; IND/CTA submissions targeted for Q4 2026."],"consensus_eps_estimate":-0.5898,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":21299000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124936,"accession_number":"0001193125-25-226878","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Metagenomi enters LNP license with Acuitas, terminates Affini-T TCR deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-exclusive Acuitas license for LNP technology; low-seven-figure annual maintenance fee until first Phase 1 dosing.","Milestone payments low to mid seven figures for regulatory/commercial events; royalties low mid-single digit % of net sales.","Terminated Affini-T agreement effective Sept 30, 2025 due to Affini-T's assignment for benefit of creditors.","Metagenomi regains full control over IP and rights to develop TCR-based therapeutics previously licensed to Affini-T.","No future payments expected from Affini-T under terminated agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141647,"accession_number":"0000950170-25-107304","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.","R&D expenses of $22.5M (down 20% YoY); G&A expenses of $7.0M (down from $8.6M).","MGX-001 hemophilia A program: IND/CTA submission planned in 2026; durable FVIII activity shown through 19 months in NHP study.","Appointed Laurence Reid, Ph.D., to Board of Directors in August 2025; established an R&D Committee.","Presented three abstracts at ASGCT on compact nucleases and CAST systems for targeted gene integration."],"consensus_eps_estimate":-0.6272,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":12640000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159536,"accession_number":"0000950170-25-084529","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Metagenomi stockholders elect Dr. Willard H. Dere as Class I Director and ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Willard H. Dere elected with 7,580,903 votes for, 2,891,893 withheld, and 8,292,425 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2025: 17,970,776 for, 252,634 against, 541,811 abstentions.","Annual meeting held June 10, 2025; quorum established with 18,765,221 shares present (50.2% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159535,"accession_number":"0000950170-25-070906","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Metagenomi presents in vivo CNS gene editing data at ASGCT; CAST integration efficiency improved >50x","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Type II nuclease MG21-1 in single AAV achieved 69% protein knockdown in mouse motor cortex and 82% in brain via systemic delivery.","Ultra-compact Type V nuclease MG119-28 (488 aa) achieved 64% target protein knockdown and up to 52% editing efficiency in mouse CNS.","Type V-K CAST system engineered for >50x improvement in large gene integration efficiency vs. natural system in mammalian cells.","In vitro, MG119-28 restored dystrophin levels >50% in DMD myocytes and achieved complete gene disruption in K562 cells.","Platform aims to enable extrahepatic in vivo gene editing for neurological and neuromuscular disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159534,"accession_number":"0000950170-25-070448","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.","Cash, equivalents, and marketable securities $226.0M as of Mar 31, 2025; runway into 2027.","R&D expenses $25.1M (Q1 2025) vs $31.4M (Q1 2024); G&A $6.8M vs $8.8M.","Published novel compact CRISPR-associated transposases in Nature Communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177905,"accession_number":"0000950170-25-040453","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Metagenomi enters $75M at-the-market equity distribution agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies to sell up to $75M of common stock via ATM offerings on Nasdaq.","Company is not obligated to sell any shares; sales are at Metagenomi's sole discretion.","Jefferies will receive a commission of up to 3.0% of gross proceeds from shares sold.","Shares to be offered under a new S-3 registration statement filed March 17, 2025.","No specific use of proceeds disclosed; proceeds may fund operations or R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177904,"accession_number":"0000950170-25-040238","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.","FY2024 R&D expense $109.2M (up from $94.4M); G&A expense $32.0M (up from $28.8M).","Hemophilia A program MGX-001: sustained FVIII activity in NHP >16 months; IND submission expected 2026.","Ionis collaboration: four Wave 1 targets in lead optimization; plans to nominate 1-2 DCs in 2025.","Board addition: Eric Bjerkholt (CFO of Mirum Pharmaceuticals) joins audit and compensation committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177903,"accession_number":"0000950170-25-006028","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Metagenomi adds Eric Bjerkholt to board; board size increases to six","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Eric Bjerkholt appointed as Class II director effective Jan 27, 2025; board expands from five to six.","Bjerkholt is CFO of Mirum Pharmaceuticals; previously CFO at Chinook, Aimmune, Sunesis.","He will serve on Audit and Compensation Committees; receives initial option grant of 42,000 shares vesting over 3 years.","Company updated investor deck for J.P. Morgan Healthcare Conference; no specific pipeline details disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194623,"accession_number":"0000950170-24-134733","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Metagenomi reports durable FVIII activity >16 mo in NHP hemophilia A study; MGX-001 IND on track for 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.","MGX-001 bioengineered FVIII showed higher activity vs wild-type at similar integration rates in separate NHP study.","No off-target editing identified to date in orthogonal assays; program targeting IND filing in 2026.","Transient liver transaminase elevation at AAV/LNP dosing; no safety findings on albumin or bilirubin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194622,"accession_number":"0000950170-24-126317","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.","Cash, cash equivalents and marketable securities $274.6M at Sept 30, 2024; cash runway expected into 2027.","R&D expenses $26.3M in Q3 2024 (vs $26.8M Q3 2023); G&A $7.6M (vs $7.9M).","Ionis collaboration: all four wave 1 programs in lead optimization; one to two DC nominations expected in 2025.","Novel ABE platform targets >95% of genome base pairs; SMART platform enables single-AAV delivery for neuromuscular."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210928,"accession_number":"0000950170-24-102805","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.","FVIII levels consistent from 3-6 month to 9-12 month time points; no significant decline.","Liver biopsy showed gene integration in forward orientation at 0.7% to 2.9%.","Treatment well tolerated with only moderate transient liver transaminase elevations.","Program on track for IND filing in 2026; company declared MGX-001 as development candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210927,"accession_number":"0000950170-24-096673","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.","Cash, cash equivalents and marketable securities of $299.9M at June 30, 2024; runway into 2027.","R&D expense $28.3M in Q2 2024 vs $22.7M in Q2 2023; G&A expense $8.6M vs $6.6M.","All four Ionis Wave 1 cardiometabolic programs in lead optimization; targeting 1–2 DC nominations in 2025.","Deprioritizing PH1 and ALS programs; pipeline guidance revised through year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":31167000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229374,"accession_number":"0000950170-24-059532","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.","Cash, equivalents and marketable securities $327.4M including $80.7M net IPO proceeds; runway into 2027.","Regained full global rights to wholly-owned base editors and RIGS; terminated PH1 collaboration with Moderna.","Hemophilia A program: development candidate nomination expected mid-2024; 12-month NHP durability data in 2H 2024.","R&D expenses $31.4M (+56% YoY); base editors expanded genome targetability 5-fold vs SpCas9."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":11159000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229373,"accession_number":"0000950170-24-051238","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["1.02","2.02","7.01","9.01"],"status":"ready","headline":"Metagenomi ends Moderna collaboration; regains full rights to base editing/RIGS; reports $327.4M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutually terminated 2021 Strategic Collaboration and License Agreement with Moderna as of April 26, 2024.","Metagenomi regains all development/commercialization rights to its wholly-owned base editing and RIGS programs.","No further payments due from Moderna under the termination agreement; future revenue stream eliminated.","Preliminary unaudited cash and cash equivalents of ~$327.4M as of March 31, 2024.","Company will hold an investor call on May 1, 2024, with updated slide presentation (Exhibit 99.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247934,"accession_number":"0000950170-24-036847","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.","Cash and equivalents $271.2M at Dec 31, 2023; plus $81.1M net IPO proceeds in Feb 2024.","Hemophilia A program achieved NHP proof of concept; development candidate nomination expected mid-2024.","Demonstrated CAST system for >10,000 bp targeted integrations and SMART base editors as small as 623 amino acids.","Cash runway supports 2 INDs and 2 additional development candidate nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247933,"accession_number":"0001193125-24-033697","cik":1785279,"company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Metagenomi adopts amended charter and bylaws in connection with IPO","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized 500M shares of common stock and 10M shares of undesignated preferred stock.","Eliminated all references to prior series of preferred stock.","Stockholders can no longer act by written consent or call special meetings.","Established advance notice procedures for stockholder proposals and director nominations.","Amendments effective upon consummation of the initial public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":51387961.87777777,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}